Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Texas
Clinical trial register · United States · industry-sponsored

Clinical Trials in Texas, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
Texas 53 California 44 Florida 32 Michigan 31 New York 29
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Gilead Sciences4 Bayer3 Eikon Therapeutics2 Vividion Therapeutics, Inc.2 LigaChem Biosciences, Inc.2
State
Texas53 California44 Florida32 Michigan31 New York29
All 40 states
Target enrolment
to

Trials with a site in Texas

53 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Merck Sharp & Dohme LLC
Phase 2
200
Texas
2026-10-07
Recruiting
LigaChem Biosciences, Inc.
Phase 1/2
191
Massachusetts, New York, South Carolina, Texas
2026-08
Recruiting
VelaVigo Bio Inc
Phase 1/2
230
California, Michigan, New York, Texas, Virginia
2026-07-30
Recruiting
Gilead Sciences
Phase 1
174
Massachusetts, Michigan, New Jersey, New York, Texas
2026-06-02
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 1
138
Connecticut, North Carolina, Texas
2026-02-13
Recruiting
PMV Pharmaceuticals, Inc
Phase 1
14
Colorado, Florida, Tennessee, Texas
2026-02-04
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC
DrugsElironrasib·Zoldonrasib·Ivonescimab·Cetuximab
Revolution Medicines, Inc.
Phase 1/2
370
California, Connecticut, Minnesota, Tennessee, Texas, Virginia
2026-01-30
Recruiting
Eikon Therapeutics
Phase 1/2
160
California, Florida, New Jersey, New York, Texas
2026-01-20
Recruiting
Amgen
Phase 2
14
Florida, Texas
2026-01-02
Recruiting
Ottimo Pharma Limited
Phase 1/2
170
Connecticut, Massachusetts, Michigan, Texas, Utah
2025-12-17
Recruiting
BTM-3566 in Advanced Solid Tumors
NCT07266285Advanced Solid Tumors
DrugBTM-3566
Bantam Pharmaceuticals
Phase 1
30
Texas
2025-12-10
Recruiting
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
NCT07197554Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC)
SEED Therapeutics, Inc.
Phase 1
171
California, Massachusetts, New York, Texas
2025-12-01
Recruiting
AstraZeneca
Phase 1
40
North Carolina, Texas, Virginia
2025-11-25
Recruiting
Sun Pharma Advanced Research Company Limited
Phase 1
177
Arizona, California, Connecticut, Illinois, Texas
2025-08-12
Recruiting
Nutshell Therapeutics (Shanghai) Co., LTD.
Phase 1/2
220
Texas
2025-08-04
Active, closed
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
NCT07038369Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms
DrugATV-1601
Atavistik Bio, Inc
Phase 1
134
California, Florida, Massachusetts, Missouri, Texas
2025-07-29
Recruiting
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
NCT07148128Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma, Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer, Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer, Advanced Solid Tumors
Auricula Biosciences Inc.
Phase 1/2
110
Texas
2025-07-28
Recruiting
FoRx Therapeutics AG
Phase 1
40
California, Michigan, Missouri, Oregon, Texas, Virginia
2025-07-22
Recruiting
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT06993844Advanced Solid Tumors, Advanced Breast Cancer
DrugFulvestrant
Ensem Therapeutics
Phase 1/2
233
California, Connecticut, Massachusetts, North Carolina, Texas, Virginia, Washington
2025-06-10
Recruiting
Tagworks Pharmaceuticals BV
Phase 1
50
Arizona, Massachusetts, Pennsylvania, Texas, Virginia
2025-05-07
Recruiting
Eikon Therapeutics
Phase 1/2
130
Colorado, Florida, Massachusetts, Texas, Virginia
2025-04-30
Recruiting
Pyxis Oncology, Inc
Phase 1/2
220
California, Florida, Illinois, Massachusetts, New York, Oklahoma, Pennsylvania, Texas
2025-04-15
Recruiting
ModernaTX, Inc.
Phase 1
42
California, Michigan, Texas, Utah
2025-03-25
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
270
Alabama, Florida, New Jersey, Texas, Virginia
2025-03-25
Recruiting
Accent Therapeutics
Phase 1/2
218
Colorado, Florida, Michigan, Missouri, Nebraska, New York, Tennessee, Texas
2025-03-21
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Florida, Georgia, Louisiana, Massachusetts, New Jersey, New York, Tennessee, Texas
2025-02-26
Recruiting
Vividion Therapeutics, Inc.
Phase 1
220
Michigan, Texas, Utah, Virginia
2025-02-25
Recruiting
CStone Pharmaceuticals
Phase 1/2
800
California, Texas
2025-02-24
Recruiting
Pikavation Therapeutics, Inc.
Phase 1/2
320
California, Massachusetts, Pennsylvania, Tennessee, Texas
2025-02-20
Recruiting
A Study of MGC028 in Participants With Advanced Solid Tumors
NCT06723236Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma
MacroGenics
Phase 1
124
California, Massachusetts, Michigan, New York, Texas, Utah
2025-02-13
Recruiting
Bayer
Phase 2
111
Alabama, California, Florida, Massachusetts, Michigan, Ohio, Tennessee, Texas
2025-02-13
Active, closed
Quanta Therapeutics
Phase 1
237
Colorado, Connecticut, Florida, Michigan, North Carolina, Tennessee, Texas, Utah
2025-01-14
Recruiting
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT06657222Advanced Solid Tumors, HNSCC, SCLC, NSCLC
Gilead Sciences
Phase 1/2
250
Connecticut, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio, Texas
2024-12-13
Active, closed
A Study of ZW191 in Participants With Solid Tumors
NCT06555744Advanced Solid Tumors
Zymeworks BC Inc.
Phase 1
145
Connecticut, Ohio, Oklahoma, Texas, Virginia
2024-10-30
Active, closed
Bristol-Myers Squibb
Phase 1
213
Arizona, California, Michigan, South Dakota, Texas
2024-10-10
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
240
California, Connecticut, Illinois, Michigan, New York, North Carolina, Pennsylvania, Texas
2024-09-23
Recruiting
Gilead Sciences
Phase 1
154
California, Massachusetts, Texas, Virginia
2024-07-26
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
500
Colorado, Connecticut, Florida, Nevada, Ohio, Texas
2024-05-01
Recruiting
PAS-004 in Patients With Advanced Solid Tumors
NCT06299839RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
DrugPAS-004
Pasithea Therapeutics Corp.
Phase 1
48
Texas, Virginia
2024-02-29
Recruiting
Gilead Sciences
Phase 1
278
Massachusetts, New York, Texas
2024-01-09
Recruiting
Shanghai YingLi Pharmaceutical Co. Ltd.
Phase 1
60
Ohio, Texas, Utah
2023-10-24
Recruiting
LigaChem Biosciences, Inc.
Phase 1/2
300
California, Massachusetts, Michigan, Tennessee, Texas
2023-10-05
Recruiting
Vividion Therapeutics, Inc.
Phase 1
290
Florida, Minnesota, Tennessee, Texas, Virginia
2023-07-28
Recruiting
Incyte Corporation
Phase 1
570
California, Massachusetts, Michigan, New Jersey, New York, Pennsylvania, Rhode Island, Texas
2023-07-24
Recruiting
Abion Inc
Phase 2
178
Florida, Michigan, Texas
2023-01-17
Active, closed
Bayer
Phase 1
284
Colorado, Pennsylvania, Texas
2022-11-04
Active, closed
Bayer
Phase 1
129
Illinois, North Carolina, Texas, Utah
2022-10-11
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2
83
Florida, Louisiana, Ohio, Rhode Island, South Carolina, Texas
2022-05-30
Active, closed
A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer
NCT04492488Advanced Solid Tumors, Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Cancer
DrugMRG002
Shanghai Miracogen Inc.
Phase 1/2
129
California, Texas
2021-05-24
Active, closed
Hoffmann-La Roche
Phase 1/2
210
Arizona, California, Massachusetts, Michigan, North Carolina, Texas
2020-09-03
Active, closed
Fujifilm Pharmaceuticals U.S.A., Inc.
Phase 1
96
Arizona, Colorado, Massachusetts, New York, Ohio, Texas, Wisconsin
2019-11-14
Active, closed
Novartis Pharmaceuticals
Phase 1
120
New York, Oregon, Texas
2019-10-30
Active, closed
Fujifilm Pharmaceuticals U.S.A., Inc.
Phase 1
90
Arizona, California, Colorado, Tennessee, Texas, Washington
2018-03-22
Rows per page Showing 1–53 of 53
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 October 2026. https://priyalifescience.com/clinical-trials-usa/state/texas

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 53 of those studies with a site in Texas that also match the filters currently applied.

How many clinical trials are recruiting in Texas?

42 of the 53 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 11 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Texas), 53 studies
PhaseStudiesRecruitingShare
Phase 1292054.7%
Phase 1/2201837.7%
Phase 2447.5%

Most active sponsors

Lead sponsors with the most studies (Texas)
Lead sponsorStudiesRecruiting
Gilead Sciences44
Bayer31
Eikon Therapeutics22
Fujifilm Pharmaceuticals U.S.A., Inc.20
LigaChem Biosciences, Inc.22
Merck Sharp & Dohme LLC22
Vividion Therapeutics, Inc.22
Abion Inc11
Accent Therapeutics11
Amgen11
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.